Clinical trials: Prostate Cancers
Prostate Cancer, Prostate Adenocarcinoma
EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer
This study is trying to find out if the combination of Androgen deprivation therapy (ADT), MRI guided high dose radiation (HDR) brachytherapy treatment (internal radiation implant procedure) and external beam radiation therapy…
- Trial name
- Prostate005 (NCT04465500)
- Testing
- External Beam Radiation, HDR Brachytherapy, Androgen Deprivation Therapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Virginia
Castration-resistant Prostate Cancer, Oligoprogressive
Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer
Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressive lesions.
- Trial name
- MEDCARE (NCT06585007)
- Testing
- Radiotherapy, metastasectomy
- Where
- Belgium
- Volunteers
- 246 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Adult Solid Tumor, Breast Cancer
Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. St. John's wort may interfere with the effectiveness of chemotherapy.
- Conditions
- Adult Solid Tumor, Breast Cancer, Head and Neck Cancer, Kidney and Urinary Cancer
- Trial name
- NCT00041171
- Testing
- Hypericum perforatum, docetaxel
- Sponsor
- Alliance for Clinical Trials in Oncology
Robotic Radical Perineal Prostatectomy
Robotic Radical Perineal Prostatectomy Study
Radical perineal prostatectomy (RPP) was the first approach utilized for the removal of the entire prostate gland for prostate cancer.
- Trial name
- NCT04919057
- Testing
- GelPOINT®
- Where
- Hong Kong
- Sponsor
- Chinese University of Hong Kong
Prostate Cancer
PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer
In this study, prostate cancer patients whose cancer has not spread to the lymph nodes will receive radiation therapy targeted to the prostate and nearby tissues with or without whole pelvis radiation therapy.
- Trial name
- NCT07291557
- Testing
- Prostate Only Radiation Therapy (PORT), Prostate + Whole Pelvis Radiation Therapy (P-WPRT)
- Where
- Canada
- Volunteers
- 250 people
- Sponsor
- AHS Cancer Control Alberta
Metastatic Hormone-sensitive Prostate Cancer
A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.
The purpose of the study is to assess if the addition of darolutamide to ADT compared with ADT alone would result in superior clinical efficacy in participants with metastatic hormone-sensitive prostate cancer (mHSPC) by…
- Trial name
- ARASEC (NCT05059236)
- Testing
- Darolutamide (BAY1841788, Nubeqa), ADT
- Where
- 31 sites in United States
- Volunteers
- 223 people
- Sponsor
- Bayer
Prostate Cancer
A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as aminoglutethimide or ketoconazole may stop the adrenal glands from producing hormones.
- Trial name
- NCT00006371
- Testing
- aminoglutethimide, ketoconazole, therapeutic hydrocortisone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Neuroendocrine Tumors, Prostate Cancer
Dual-Tracer Theranostic PET
This study is designed to obtain positron emission tomography with x-ray computed tomography (PET/CT) imaging data with each tracer pair, providing the imaging data needed to develop new simultaneous dual-tracer imaging…
- Trial name
- NCT05680675
- Testing
- Single-Tracer FDG PET/CT Exam, Single-Tracer Cu64-DOTATATE PET/CT Exam, Single-Tracer Ga68-DOTATATE PET/CT Exam
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Utah
Prostate Cancer
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)
Adult male patients with high-risk, localized prostate cancer and planning to undergo radiation therapy (RT) with androgen deprivation therapy (ADT) will undergo an advanced Magnetic Resonance Imaging (MRI) examination called…
- Trial name
- ProsRSI (NCT04349501)
- Testing
- Restriction Spectrum Imaging Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, San Diego
Bladder Cancer, Breast Cancer
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
RATIONALE: OGX-011 may kill tumor cells by blocking some of the proteins that may cause tumor cells to grow. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Conditions
- Bladder Cancer, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00471432
- Testing
- custirsen sodium, docetaxel, pharmacological study
- Volunteers
- 40 people
- Sponsor
- NCIC Clinical Trials Group
Prostatectomy, Prostate Cancer
Physical Activity Intervention in African American Men After Radical Prostatectomy
The purpose of this pilot study is to evaluate the feasibility of recruiting African American prostate cancer survivors to a 12 week physical activity intervention study of three arms (aerobics, resistance training, and usual…
- Trial name
- NCT02621684
- Testing
- Community Health Activities Model Program for Seniors (CHAMPS), Lifetime Total Physical Activity Questionnaire, Expanded Prostate Cancer Index Composite (EPIC)
- Sponsor
- Washington University School of Medicine
Prostate Cancer
Identification of Prostate Cancer Genes
This study will identify genes that predispose men to prostate cancer and affect the rate and type of disease spread, the aggressiveness of the disease, and the long-term outcome.
- Trial name
- NCT00342784
- Where
- United States
- Volunteers
- 5,118 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Prostate Cancer
Energy Balance for Prostate Cancer Survivorship
The purpose of this study is to evaluate the effectiveness of a weight management program for men undergoing a prostatectomy by seeing if the program is easy to follow, impacts weight gain, and reduces risk of cancer recurrence…
- Trial name
- NCT02252484
- Testing
- Weight Loss Program, Standard of Care
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jill Hamilton-Reeves, PhD RD LD
Prostate Cancer Adenocarcinoma, Erectile Dysfunction Following Radical Prostatectomy
Use of Indocyanine Green in Robotic Prostate Surgeries
Imaging of the vascular nerve bundle using Indocyanine Green
- Trial name
- NCT05960149
- Testing
- using Indocyanine Green, Nerve-sparing robot-assisted laparoscopic radical prostatectomy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Ankara University
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone
Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases
This phase II trial is studying how well fluorine F 18 sodium fluoride positron emission tomography (PET) works in evaluating response to dasatinib in patients with prostate cancer and bone metastases.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT00936975
- Testing
- Fluorine F 18 Sodium Fluoride
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007
The aim of this study is to provide robust data on the head-to-head comparison of the two ligands of the prostate specific membrane antigen (PSMA) available in Switzerland for positron emission tomography (PET)-imaging, i.e.
- Trial name
- NCT05079828
- Testing
- 18F-PSMA-1007, 68Ga-PSMA-11
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Sexual Dysfunction, Breast Cancer
An Intimacy Intervention for Couples Completing Breast or Prostate Cancer
This project seeks to help patients address and improve intimacy at the end of treatment for breast or prostate cancer. It is intended to address the needs of cancer survivors, broadly defined as paftients and their loved ones or…
- Conditions
- Sexual Dysfunction, Breast Cancer, Prostate Cancer
- Trial name
- NCT04221607
- Testing
- Sensate Focus exercise
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Brown University
Prostate Cancer
Exosomal microRNA in Predicting the Aggressiveness of Prostate Cancer in Chinese Patients
The prostate gland is a clinically important male accessory sex gland and vital for its production of semen. Prostate cancer (PCa) is now ranked 3th in annual incidence of male cancer and ranked 5th for cancer-related death in…
- Trial name
- NCT03911999
- Where
- Hong Kong
- Volunteers
- 180 people
- Sponsor
- Chinese University of Hong Kong
Prostate Cancer XXX
The Effect of TENS on Pain, Complications and Comfort in Patients Who Had Prostate Biopsy With Transrectal Ultrasound
Prostate cancer is one of the most common types of malignancy in men. Transrectal Ultrasound Guided Prostate Biopsy (TRUSG-PBx) is considered the gold standard method.
- Trial name
- NCT06414421
- Testing
- Transcuten Electriacal Nerve Stimulation
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Cukurova University
Prostate Cancer
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
The purpose of this study is to see what effects, good and/or bad, proton radiation, and/or conventional radiation and hormonal therapy (if applicable), has on prostate cancer that has already returned or the risk of prostate…
- Trial name
- NCT00969111
- Testing
- IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE, Proton (prostate bed) to 70.2 CGE, IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE
- Where
- 6 sites in United States
- Volunteers
- 70 people
- Sponsor
- Proton Collaborative Group